Description:

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy; ODM derived from: https://clinicaltrials.gov/show/NCT01402180

Link:

https://clinicaltrials.gov/show/NCT01402180

Keywords:
Versions (1) ▾
  1. 12/16/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

December 16, 2019

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Esophageal Squamous Cell Carcinoma NCT01402180

Eligibility Esophageal Squamous Cell Carcinoma NCT01402180

Inclusion Criteria
1. age ≥ 18 and ≤75
2. ecog performance status 0-2
3. histologically proven primary thoracic esophageal squamous cell carcinoma before
4. diagnosis of regional lymph nodes (biosupravascular fossa or upper mediastinum) recurrence after radical esophagectomy, based on pathological finding or imaging showing lymph nodes enlargement
5. period from esophagectomy to diagnosis of regional lymph nodes recurrence should be more than 6 months
6. without prior radiotherapy
7. weight loss no more than 10% in the past 6 months
8. wbc≥ 4.0x109/l ,absolute neutrophil count (anc) ≥ 2.0x109/l
9. platelets ≥ 100x109/l
10. hemoglobin ≥ 90g/l(without blood transfusion)
11. ast (sgot)/alt (sgpt) ≤ 2.5 x upper limit of normal, bilirubin ≤ 1.5 x upper limit of normal
12. creatinine ≤ 1.5 x upper limit of normal
13. sign study-specific informed consent prior to study entry
Exclusion Criteria
1. with recurrence or metastasis other than regional lymph nodes (biosupravascular fossa or upper mediastinum)
2. prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
3. severe, active comorbidity, defined as follows:
3.1 unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months 3.2 transmural myocardial infarction within the last 6 months 3.3 acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration 3.4 chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration 3.5 acquired immune deficiency syndrome (aids) based upon current cdc definition; note, however, that hiv testing is not required for entry into this protocol. the need to exclude patients with aids from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
4. pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
5. prior radiation therapy or prior target drug therapy